Approved regulatory verdict
Evidence outlook
Approved: Acute Myeloid Leukemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Acute Myeloid Leukemia · approved · Featured evidence · 1 Leukemia, Promyelocytic, Acute · not a covered market · Outside covered markets · 1 approved Featured evidence · 1
Competitive landscape 60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗ Drug Stage Modality Mechanism Evidence signal Reported efficacygraded featured trials Tretinoin (Vesanoid): this drug Approved Small molecule RARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APL ASTX727 Approved Small molecule Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition) Enasidenib Approved Small molecule IDH2 Gemtuzumab Ozogamicin Approved Antibody–drug conjugate CD33 Gilteritinib Approved Small molecule FLT3 Midostaurin Approved Small molecule FLT3;KIT;PKC;PDGFR Olutasidenib Approved Small molecule Mutant IDH1 Quizartinib Approved Small molecule FLT3 Revumenib Approved Small molecule Menin Venetoclax Approved Small molecule BCL-2 Vyxeos Approved Small molecule DNA synthesis (cytarabine, antimetabolite) / Topoisomerase II 131I-Apamistamab Phase 3 Monoclonal antibody CD45 AK117 Phase 3 Monoclonal antibody CD47 APG-2575(Lisaftoclax ) Phase 3 Small molecule BCL-2 Azacitidine Phase 3 Small molecule DNMT1 (DNA methyltransferase 1) BGB-11417 Phase 3 — BCL-2
…and 45 more. Research shows the complete landscape.
Research Unlock the full comparison Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Unlock with Research ↗ Upcoming events (27 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (15) January 2027 (2) Phase 2 Dup15q Syndrome, Autism Spectrum Disorder, Therapy, All-trans Retinoic Acid Not yet recruiting
Est. primary completion 2027-01 ·
NCT07079696 ·
CT.gov ↗ What to watch Phase 4 Melasma, Melasma (Facial Melasma) Not yet recruiting
Est. primary completion 2027-01-14 ·
NCT07732192 ·
CT.gov ↗ What to watch March 2027 (2) Phase 1 Advanced Pancreatic Ductal Adenocarcinoma Not yet recruiting
Est. primary completion 2027-03 ·
NCT07348107 ·
CT.gov ↗ What to watch Phase 3 Acute Myeloid Leukemia Recruiting
Est. primary completion 2027-03 ·
NCT07504458 ·
CT.gov ↗ What to watch June 2027 (3) Phase 3 Acute Myeloid Leukemia Not yet recruiting
Est. primary completion 2027-06 ·
NCT07296445 ·
CT.gov ↗ What to watch Phase 2 Glioma, IDH Mutation, Astrocytoma, Oligodendroglioma Recruiting
Est. primary completion 2027-06-01 ·
NCT05345002 ·
CT.gov ↗ What to watch Phase 2 B-cell Non Hodgkin Lymphoma Not yet recruiting
Est. primary completion 2027-06-01 ·
NCT06646666 ·
CT.gov ↗ What to watch July 2027 (2) Phase 2 Metastatic Solid Tumor, Locally Advanced Solid Tumor Recruiting
Est. primary completion 2027-07 ·
NCT06358677 ·
CT.gov ↗ What to watch Early phase / not applicable Acute Myeloid Leukemia Active not recruiting
Est. primary completion 2027-07-01 ·
NCT07187505 ·
CT.gov ↗ What to watch October 2027 (2) Phase 2 Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers, Ovarian Cancer … Recruiting
Est. primary completion 2027-10-31 ·
NCT07586826 ·
CT.gov ↗ What to watch Phase 2 Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gastrointestinal Neoplasms … Recruiting
Est. primary completion 2027-10-31 ·
NCT07586813 ·
CT.gov ↗ What to watch December 2027 (4) Phase 2 Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, B-cell Lymphoma Recruiting
Est. primary completion 2027-12 ·
NCT06484920 ·
CT.gov ↗ What to watch Phase 2 Acute Myeloid Leukemia Recruiting
Est. primary completion 2027-12-18 ·
NCT01409161 ·
CT.gov ↗ What to watch Phase 3 Immune Thrombocytopenia Not yet recruiting
Est. primary completion 2027-12-30 ·
NCT07597395 ·
CT.gov ↗ What to watch Phase 2 Leiomyosarcoma, Sarcoma Recruiting
Est. primary completion 2027-12-31 ·
NCT06528769 ·
CT.gov ↗ What to watch 2028 (6) June 2028 (3) Phase 3 APL Recruiting
Est. primary completion 2028-06 ·
NCT07503730 ·
CT.gov ↗ What to watch Phase 2/3 Hemophagocytic Lymphohistiocytosis (HLH) Not yet recruiting
Est. primary completion 2028-06-01 ·
NCT07626398 ·
CT.gov ↗ What to watch Phase 2 Pancreatic Cancer Active not recruiting
Est. primary completion 2028-06-29 ·
NCT04241276 ·
CT.gov ↗ What to watch October 2028 (1) Phase 1 EGFR-TKI-resistant Non-Small Cell Lung Cancer Not yet recruiting
Est. primary completion 2028-10-01 ·
NCT07842887 ·
CT.gov ↗ What to watch December 2028 (2) Phase 2/3 ITP - Immune Thrombocytopenia Not yet recruiting
Est. primary completion 2028-12 ·
NCT07278908 ·
CT.gov ↗ What to watch Early phase / not applicable Acute Myeloid Leukemia Not yet recruiting
Est. primary completion 2028-12-15 ·
NCT06841952 ·
CT.gov ↗ What to watch 2029 (5) January 2029 (1) Phase 2 Rhabdomyosarcoma Not yet recruiting
Est. primary completion 2029-01 ·
NCT07355855 ·
CT.gov ↗ What to watch July 2029 (1) Phase 1/2 Multiple Myeloma Recruiting
Est. primary completion 2029-07 ·
NCT06536413 ·
CT.gov ↗ What to watch September 2029 (1) Phase 2 Triple Negative Breast Cancer (TNBC) Recruiting
Est. primary completion 2029-09 ·
NCT06636981 ·
CT.gov ↗ What to watch November 2029 (1) Phase 2 Esophageal Squamous Cell Carcinoma Not yet recruiting
Est. primary completion 2029-11-20 ·
NCT06703047 ·
CT.gov ↗ What to watch December 2029 (1) Phase 3 Ganglioneuroblastoma, Nodular, Neuroblastoma Recruiting
Est. primary completion 2029-12-31 ·
NCT06172296 ·
CT.gov ↗ What to watch 2030 (1) September 2030 (1) Phase 3 Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma Recruiting
Est. primary completion 2030-09-30 ·
NCT03126916 ·
CT.gov ↗ What to watch See the full readout calendar ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.
All indications (259) Acute Myeloid Leukemia (61) Other / comorbidity (198)
Phase 3 (47) Phase 2/3 (8) Phase 2 (85) Phase 1/2 (26) Phase 1 (45) Phase 4 (30) Early phase / not applicable (18) Used as active comparator (7) Appears in other studies (103)